This is a working overview of Semax, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-09. Anything still debated is marked as such rather than presented as settled.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
Saliva moistens and softens food, and along with the chewing action of the teeth, transforms the food into a smooth bolus. The bolus is further helped by the lubrication provided by the saliva in its passage from the mouth into the esophagus. Also of importance is the presence in saliva of the digestive enzymes amylase and lipase. Amylase starts to work on the starch in carbohydrates, breaking it down into the simple sugars of maltose and dextrose that can be further broken down in the small intestine. Saliva in the mouth can account for 30% of this initial starch digestion. Lipase starts to work on breaking down fats. Lipase is further produced in the pancreas where it is released to continue this digestion of fats. The presence of salivary lipase is of prime importance in young babies whose pancreatic lipase has yet to be developed. As well as its role in supplying digestive enzymes, saliva has a cleansing action for the teeth and mouth. It also has an immunological role in supplying antibodies to the system, such as immunoglobulin A. This is seen to be key in preventing infections of the salivary glands, importantly that of parotitis. Saliva also contains a glycoprotein called haptocorrin which is a binding protein to vitamin B12. It binds with the vitamin in order to carry it safely through the acidic content of the stomach. When it reaches the duodenum, pancreatic enzymes break down the glycoprotein and free the vitamin which then binds with intrinsic factor.
This category includes the Community of Latin American and Caribbean States (CLACS), Council of Europe (CoE), European Union (EU), Eurasian Economic Union (EAEU), Energy Community, North Atlantic Treaty Organization (NATO), Economic Community of West African States (ECOWAS), Organization for Security and Co-operation in Europe (OSCE), African Union (AU), Organization of American States (OAS), Association of Caribbean States (ACS), Association of Southeast Asian Nations (ASEAN), Islamic Development Bank, Union of South American Nations, Asia Cooperation Dialogue (ACD), Pacific Islands Forum, South Asian Association for Regional Cooperation (SAARC), Asian-African Legal Consultative Organization (AALCO) and the Organisation of Eastern Caribbean States (OECS).
The underconnectivity theory of autism posits that autistic people tend to have fewer high-level neural connections and less global synchronization, along with an excess of low-level processes. Functional connectivity studies have found both hypo- and hyperconnectivity in brains of autistic people. Hypoconnectivity is commonly observed for interhemispheric (e.g. lower neuron density in corpus callosum) and cortico-cortical functional connectivity. Some studies have found local overconnectivity in the cerebral cortex and weak functional connections between the frontal lobe and the rest of the cortex. Abnormal default mode network (task-negative) connectivity is often observed. Toggling between task-negative network activation and task-positive network activation (consisting of the dorsal attention network and salience network) may be less efficient, possibly reflecting a disturbance of self-referential thought. Such patterns of low function and aberrant activation in the brain may depend on whether the brain is performing social or nonsocial tasks. Some studies have suggested that autism is a disorder of the association cortex. Event-related potentials with respect to attention, orientation to auditory and visual stimuli, novelty detection, language and face processing, and information storage are altered in autistic individuals; several studies have found a preference for nonsocial stimuli. Magnetoencephalography studies have observed delayed processing of auditory signals in autistic children.
The pharmacology of 3-CMC is expected to be very similar to the pharmacology for other mephedrone analogs (methcathinones). These molecules interact with monoamine transporters, in particular the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) . The main function of these transporters is to terminate monoamine transmission by reuptake of the released neurotransmitters. Interaction of psychoactive drugs with the monoamine transporters inhibits this reuptake leading to an increase in the concentration of dopamine, norepinephrine and serotonin in the synaptic cleft. Specifically, 3-chloromethcathinone (3-CMC) and other ring-substituted methcathinone derivatives act as substrates for monoamine transporters MATs (and subsequently competitive inhibitors), through which they are actively translocated into the cytoplasm of the presynaptic nerve terminal. Once inside the cytosol, they interact with the vesicular monoamine transporter 2 (VMAT2) as substrates, disrupting the vesicular proton gradient and facilitating the collapse of synaptic vesicles. This causes the release of stored neurotransmitters into the cytoplasm. The resulting high concentration of cytosolic neurotransmitters subsequently triggers the reversal of MAT transport direction, leading to carrier-mediated efflux of the neurotransmitters into the synaptic cleft. Furthermore, simple ring-substituted cathinones contrast with traditional amphetamines by lacking significant affinity for the intracellular trace amine-associated receptor 1 (TAAR1).
Sources: en.wikipedia.org
The absorption rate constant Ka is a value used in pharmacokinetics to describe the rate at which a drug enters into the system. It is expressed in units of time−1. The Ka is related to the absorption half-life (t1/2a) per the following equation: Ka = ln(2) / t1/2a. Ka values can typically only be found in research articles. This is in contrast to parameters like bioavailability and elimination half-life, which can often be found in drug and pharmacology handbooks.
24 June NASA publishes images showing an unexpected and unexplained double crater from what is thought to be the first time human space debris – likely by a spent rocket body – unintentionally hit the lunar surface on 4 March. Early 2022 monkeypox outbreak research:A study reports phylogenomic characterization of the first monkeypox (MP) virus outbreak genome sequences, finding the "presumably slow-evolving" DNA virus has evolved roughly 6–12-fold more mutations than one would expect and 15 SNP mutations since the beginning of the outbreak. The WHO announces that MP is not yet a global public health emergency but a cause for deep concern (25 June). Early overviews and reviews, including about current knowledge about MP prevention and treatment, are published. Scientists are investigating circulating lineages (and potential variants) of the MP virus and compare them to the African endemic lineages. A preprint suggests that cases "where a small fraction of individuals have disproportionately large numbers of partners, can explain the sustained growth of monkeypox cases among the MSM population" (13 June). The MP incubation period is estimated to be 8.5 days on average and up to 21 days (16 June). The 3D-folded structures of the whole proteome of the current DNA virus are predicted, which may be useful for the development of (better or updated) vaccines and drugs (28 June). A study indicates MP contaminated surfaces within hospitals and households could be infectious (30 June).
Other compounds other than radiolabelled somatostatin receptor antagonists have also been studied. Cyclosomatostatin is one such compound. Contrary to previously discussed compounds, cyclosomatostatin does not contain a radionuclide. It is a non-selective somatostatin receptor antagonist, inhibiting the effects of somatostatin on target cells in the gastrointestinal tract, pancreas, hypothalamus, and central nervous system. Cyclosomatostatin is used as a research chemical to investigate the effects of somatostatin on different cell types by antagonizing its receptors. However it acts as an agonist in SH-SY5Y neuroblastoma cells. Cyclosomatostatin is also known by the following names:
The body of 18-year-old Hannah Lynch, daughter of Mike Lynch, is recovered from the Bayesian, making her the seventh and final victim of the sinking. Storm Lilian brings disruption to much of the UK, with gusts of up to 70 mph in some regions. The Energy Price Cap is set to rise by 10% in October, with the average household price for gas and electricity increasing by £149 per year. A report by the United Nations urges the UK to take measures to curb race hate speech, including by politicians. 24–26 August – Eight people are stabbed during the Notting Hill Carnival, with a total of 334 people being arrested during the event. 24 August Data from the Office for National Statistics shows the number of those aged 16–24 not in employment, education or training rose to 872,000 during the period of April to June 2024. British athletes Helene Raynsford and Gregor Ewan light the Paralympic Flame at Stoke Mandeville, ahead of its journey to Paris for the 2024 Summer Paralympics. 25 August EE, one of the UK's largest mobile phone networks, advises parents not to give primary school age children smartphones after receiving an increase in the number of requests for guidance from parents. A British Reuters employee named as Ryan Evans is confirmed as having been killed in a missile attack on a hotel in Ukraine the previous day. 26 August A major incident is declared as a fire engulfs a block of flats in Dagenham, east London, which had "known" safety issues. More than 100 people are evacuated, with two taken to hospital.
Bruker develops and delivers a wide variety of professional and scientific analysis devices including mass spectrometers, single-Crystal and powder X-ray diffractometers, X-ray tomography devices, NMR spectroscopy devices, fluorescence microscopes, raman spectroscopes, atomic-force microscopes, and profilometers.
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.